TipRanks
Go Ultimate55% OFF

VSee Health (VSEE) AI Stock Analysis

Top Page

VSEE

VSee Health

(Other OTC:VSEE)

Select Model
Rating:44Neutral
Price Target:$1.50â–¼(-15.73% Downside)
Action:reiterated
Date:10/01/26

The score is mainly held back by weak financial performance—declining revenue, very large losses, and sustained negative operating/free cash flow—despite manageable current leverage. Technicals also weigh on the score with the price below key moving averages and a negative MACD. Valuation is only modestly supportive because negative earnings make the P/E difficult to rely on and no dividend yield is available.

Positive Factors
Telehealth platformVSee Health operates in the structurally growing virtual-care infrastructure market, providing software and services that support remote consultations and digital workflows. This platform-based model can serve multiple healthcare settings and enables customers to build virtual-first programs around recurring operational needs.
Negative Factors
Revenue contractionThe recent reversal from strong 2024–2025 growth to a 12.6% TTM revenue decline weakens operating scale and makes fixed costs harder to absorb. Unless demand and customer adoption recover, lower revenue can prolong losses, reduce investment capacity, and undermine the platform’s ability to compound sustainably.

VSee Health (VSEE) vs. SPDR S&P 500 ETF (SPY)

-100%-75%-50%-25%0%25%VSEE-97.82%SPY+11.79%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
$1.55M
Dividend Yield
―
Average Volume (3M)
41.44K
Price to Earnings (P/E)
-0.0
Beta (1Y)
0.61
Revenue Growth
-9.31%
EPS Growth
89.42%
Country
US
Employees
209
Sector
Healthcare
Sector Strength
51
Industry
Medical - Healthcare Information Services

VSee Health Business Overview & Revenue Model

Company Description

VSee Health, Inc. specializes in delivering virtual healthcare solutions. Their flagship offering, iDoc Telehealth, is specifically designed to manage and coordinate comprehensive care for severely ill individuals within various critical care environ...

VSee Health Financial Statement Overview

Summary

Financials are pressured by contracting TTM revenue (~$12.6M, down ~12.6%) and very weak profitability (net margin around -110%) alongside persistent cash burn (TTM operating and free cash flow both about -$5.2M). The balance sheet is less concerning near-term with modest debt (~$1.9M) and moderate leverage (debt-to-equity ~0.25), but ongoing losses keep overall financial quality weak.

Income Statement

23Negative

Balance Sheet

46Neutral

Cash Flow

18Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue12.63M14.62M10.42M5.77M6.38M7.34M
Gross Profit4.76M7.36M7.18M3.83M4.84M5.92M
EBITDA-9.03M-9.18M-3.30M-1.79M0386.34K
Net Income-13.82M-14.71M-57.70M-3.76M-836.21K475.90K
Balance Sheet
Total Assets16.73M22.41M19.99M805.79K2.61M117.94M
Cash, Cash Equivalents and Short-Term Investments454.15K5.27M326.12K118.73K230.66K760.01K
Total Debt1.88M2.44M9.55M543.00K517.13K0
Total Liabilities9.14M16.96M20.01M5.11M2.61M4.55M
Stockholders Equity7.59M5.45M-18.49K-3.97M360.72K113.39M
Cash Flow
Free Cash Flow-6.32M-3.48M-5.84M-636.93K-1.45M-600.11K
Operating Cash Flow-6.31M-3.45M-5.79M-632.60K-1.45M-600.11K
Investing Cash Flow-143.21K-29.93K-26.14K-4,335110.12M-116.73M
Financing Cash Flow6.83M8.42M6.02M525.00K-109.32M118.09M

VSee Health Technical Analysis

Technical Analysis SentimentNegative
Last Price1.78

Price Trends

50DMA1.68Positive
100DMA4.34Negative
200DMA12.72Negative

Market Momentum

MACD-0.02Negative
RSI45.22Neutral
STOCH90.87Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VSEE, the sentiment is Negative. The current price of 1.78 is below the 20-day moving average (MA) of 1.91, above the 50-day MA of 1.68, and below the 200-day MA of 12.72, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 45.22 is Neutral, neither overbought nor oversold. The STOCH value of 90.87 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VSEE.

VSee Health Risk Analysis

VSee Health disclosed 62 risk factors in its most recent earnings report. VSee Health reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

1 New Risk
1.The Company is currently subject to a delisting determination by the staff of Nasdaq, and trading of its common stock was halted on August 6, 2026. The Company expects that after its common stock is delisted from Nasdaq, its common stock will begin trading on the OTC Pink Limited Market, which may affect the market price and liquidity of the shares and could limit the Company's ability to raise additional capital.Q2, 2026

VSee Health Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

VSEE against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
AMWLAMWL53Neutral$216.52M-2.67-33.27%―-19.00%40.98%
TDOCTDOC52Neutral$1.55B-9.89-11.63%―-2.38%32.73%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
VSEEVSEE44Neutral$1.43M-0.05-400.87%―-9.31%89.42%
ZCMDZCMD43Neutral$4.53M-0.01-32.44%―-49.58%-31.56%

* Healthcare Sector Average

Performance Comparison

-100%0%100%VSEETDOCZCMDAMWLONMDEUDADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
VSEE and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
VSEEVsee Health, Inc.1.78-77.42-97.75%
TDOCTeladoc Inc.8.510.374.55%
ZCMDZhongchao Inc1.02-1070.34-99.90%
AMWLAmerican Well Corporation12.737.64150.10%
ONMDOnemednet Corp4.22-13.48-76.16%
EUDAEuda Health Holdings Limited17.70-29.70-62.66%

VSee Health Corporate Events

Regulatory Filings and ComplianceStock Split

VSee Health Announces 1-for-80 Reverse Stock Split

Neutral
Sep 23, 2026

On September 22, 2026, VSee Health, Inc. filed a Certificate of Amendment to implement a 1-for-80 reverse stock split of its common stock, effective at 5:00 p.m. Eastern on September 23, 2026, with split-adjusted trading to begin on September 24, 202...

Business Operations and StrategyPrivate Placements and Financing

VSee Health Pursues Private Equity Financing Strategy

Neutral
Sep 9, 2026

VSee Health disclosed that it is issuing Commitment Fee Shares and additional common stock under a Strata Agreement through a private offering structure rather than a public securities issuance. The company is relying on exemptions under Section 4(a)...

Executive/Board ChangesShareholder MeetingsStock Split

VSee Health Shareholders Approve Reverse Split Flexibility

Positive
Aug 26, 2026

On August 25, 2026, VSee Health, Inc. held its annual meeting of stockholders for the fiscal year ended December 31, 2026, with a quorum representing 50.65% of voting shares present in person or by proxy. Shareholders elected directors Kevin Lowdermi...

Delistings and Listing ChangesRegulatory Filings and Compliance

VSee Health Faces Nasdaq Trading Suspension and Delisting

Negative
Aug 4, 2026

On September 24, 2025, VSee Health disclosed that it had fallen out of compliance with Nasdaq’s Bid Price Rule after its shares traded below $1.00 for 30 consecutive sessions, triggering an initial 180‑day cure period later extended to Se...

Business Operations and StrategyPrivate Placements and Financing

VSee Health Raises Capital Through Convertible Debt Financing

Neutral
Jul 31, 2026

On June 30, 2026, VSee Health, Inc. entered into a securities purchase agreement with institutional investor Labrys, issuing an unsecured convertible promissory note with a principal amount of $336,000, including a $36,000 original issue discount, an...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 01, 2026